25.43
price down icon2.86%   -0.75
pre-market  Pre-market:  25.37   -0.06   -0.24%
loading
Enliven Therapeutics Inc stock is traded at $25.43, with a volume of 151.05K. It is down -2.86% in the last 24 hours and down -12.31% over the past month. Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
See More
Previous Close:
$26.18
Open:
$26.25
24h Volume:
151.05K
Relative Volume:
0.62
Market Cap:
$1.24B
Revenue:
-
Net Income/Loss:
$-82.83M
P/E Ratio:
-20.49
EPS:
-1.2413
Net Cash Flow:
$-72.22M
1W Performance:
-1.43%
1M Performance:
-12.31%
6M Performance:
+5.96%
1Y Performance:
+141.27%
1-Day Range:
Value
$24.98
$26.48
1-Week Range:
Value
$23.70
$27.20
52-Week Range:
Value
$9.80
$30.03

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name
Name
Enliven Therapeutics Inc
Name
Phone
720-647-8519
Name
Address
6200 LOOKOUT ROAD, BOULDER
Name
Employee
57
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
ELVN's Discussions on Twitter

Compare ELVN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ELVN 25.43 1.24B 0 -82.83M -72.22M -1.2413
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-29-23 Initiated Jefferies Buy

Enliven Therapeutics Inc Stock (ELVN) Latest News

pulisher
Nov 19, 2024

Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Increases By 6.1% - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by First Turn Management LLC - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Robert W. Baird Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price - Defense World

Nov 19, 2024
pulisher
Nov 16, 2024

Enliven Therapeutics has cash runway into late 2026 - BizWest

Nov 16, 2024
pulisher
Nov 15, 2024

Robert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

RA Capital Management, L.P. Reduces Stake in Enliven Therapeutics Inc. - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Citadel Advisors LLC Adjusts Stake in Enliven Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

COMMODORE CAPITAL LP Expands Stake in Enliven Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Enliven Therapeutics Reports Q3 Results and Clinical Progress - TipRanks

Nov 14, 2024
pulisher
Nov 13, 2024

Polar Capital Holdings Plc's Strategic Acquisition in Enliven Th - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Enliven Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024
pulisher
Nov 11, 2024

(ELVN) Investment Analysis and Advice - Stock Traders Daily

Nov 11, 2024
pulisher
Nov 07, 2024

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference - StockTitan

Nov 07, 2024
pulisher
Nov 01, 2024

How to Take Advantage of moves in (ELVN) - Stock Traders Daily

Nov 01, 2024
pulisher
Oct 31, 2024

Jones Trading Initiates Coverage of Enliven Therapeutics (ELVN) with Buy Recommendation - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Oct 31, 2024
pulisher
Oct 31, 2024

Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 By Investing.com - Investing.com South Africa

Oct 31, 2024
pulisher
Oct 30, 2024

Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 - Investing.com

Oct 30, 2024
pulisher
Oct 27, 2024

Enliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02 - MSN

Oct 27, 2024
pulisher
Oct 23, 2024

Enliven Therapeutics CFO sells $24,422 in stock By Investing.com - Investing.com Australia

Oct 23, 2024
pulisher
Oct 22, 2024

Enliven Therapeutics CFO sells $24,422 in stock - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Enliven Therapeutics chief medical officer sells $24,482 in stock By Investing.com - Investing.com Canada

Oct 22, 2024
pulisher
Oct 22, 2024

Enliven Therapeutics chief medical officer sells $24,482 in stock - Investing.com India

Oct 22, 2024
pulisher
Oct 22, 2024

Enliven Therapeutics COO Anish Patel sells $21,482 in stock - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Enliven Therapeutics COO Anish Patel sells $21,482 in stock By Investing.com - Investing.com Australia

Oct 22, 2024
pulisher
Oct 22, 2024

Enliven Therapeutics' chief scientific officer sells $25,412 in stock By Investing.com - Investing.com Australia

Oct 22, 2024
pulisher
Oct 22, 2024

Enliven Therapeutics CEO Kintz sells $27,722 in stock - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Enliven Therapeutics' chief scientific officer sells $25,412 in stock - Investing.com India

Oct 22, 2024
pulisher
Oct 22, 2024

Enliven Therapeutics director Heyman sells $47,104 in stock By Investing.com - Investing.com Australia

Oct 22, 2024
pulisher
Oct 22, 2024

Enliven Therapeutics CEO Kintz sells $27,722 in stock By Investing.com - Investing.com Australia

Oct 22, 2024
pulisher
Oct 22, 2024

Enliven Therapeutics director Heyman sells $47,104 in stock - Investing.com India

Oct 22, 2024
pulisher
Oct 22, 2024

Anish Patel Sells 716 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - MarketBeat

Oct 22, 2024
pulisher
Oct 21, 2024

When (ELVN) Moves Investors should Listen - Stock Traders Daily

Oct 21, 2024
pulisher
Oct 21, 2024

Enliven Therapeutics, Inc. (ELVN) Is a Great Choice for 'Trend' Investors, Here's Why - MSN

Oct 21, 2024
pulisher
Oct 19, 2024

ELVN stock soars to 52-week high, reaching $28.66 By Investing.com - Investing.com Australia

Oct 19, 2024
pulisher
Oct 18, 2024

Enliven Therapeutics (NASDAQ:ELVN) Reaches New 52-Week HighHere's Why - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

Richard A. Heyman Sells 1,270 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - MarketBeat

Oct 17, 2024
pulisher
Oct 15, 2024

Enliven Therapeutics Inc [ELVN] Insider Lyssikatos Joseph P sells 37,878 Shares - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Enliven Therapeutics Inc (ELVN) stock analysis: A simple moving average approach - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

Financial Metrics Check: Enliven Therapeutics Inc (ELVN)’s Ratios for Trailing Twelve Months - The Dwinnex

Oct 15, 2024
pulisher
Oct 15, 2024

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Update - MarketBeat

Oct 15, 2024
pulisher
Oct 14, 2024

Enliven Therapeutics, Inc. Is a Great Choice for 'Trend' Investors, Here's Why - Benzinga

Oct 14, 2024
pulisher
Oct 10, 2024

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 10,420 Shares of Stock - MarketBeat

Oct 10, 2024
pulisher
Oct 10, 2024

Enliven Therapeutics executive sells over $1.4 million in company stock - Investing.com India

Oct 10, 2024
pulisher
Oct 10, 2024

Enliven Therapeutics director sells over $290k in company stock - Investing.com

Oct 10, 2024
pulisher
Oct 10, 2024

Enliven Therapeutics director sells over $290k in company stock By Investing.com - Investing.com UK

Oct 10, 2024
pulisher
Oct 10, 2024

Enliven Therapeutics (NASDAQ:ELVN) Trading Down 5.6%What's Next? - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

Enliven Therapeutics CFO sells over $300k in company stock By Investing.com - Investing.com South Africa

Oct 09, 2024

Enliven Therapeutics Inc Stock (ELVN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):